V. Hagelstein

Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center

D. Zillikens, P. Terheyden, E. Langan, 2022, International journal of molecular sciences.

Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?

D. Zillikens, P. Terheyden, E. Langan, 2022, Melanoma research.

Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure

D. Zillikens, P. Terheyden, A. Recke, 2021, Melanoma research.

Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).

U. Jaehde, S. Mitchell, I. Ortland, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of the Covid-19 pandemic on quality of life in skin cancer patients

H. Busch, D. Zillikens, P. Terheyden, 2021, PloS one.

Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study

S. Haferkamp, M. Gaiser, R. Gutzmer, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.